Get the Stockscreener App
3.83
4.49%
-0.18
After Hours:
3.90
0.07
+1.83%
X 4 Pharmaceuticals Inc stock is traded at $3.83, with a volume of 445.23K.
It is down -4.49% in the last 24 hours and down -8.81% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$4.01
Open:
$4
24h Volume:
445.23K
Relative Volume:
1.06
Market Cap:
$361.24M
Revenue:
$35.11M
Net Income/Loss:
$-79.20M
P/E Ratio:
-0.8832
EPS:
-4.3367
Net Cash Flow:
$-88.62M
1W Performance:
-11.14%
1M Performance:
-8.81%
6M Performance:
-3.77%
1Y Performance:
+3.51%
1-Day Range:
$3.76
$4.0202
1-Week Range:
$3.76
$4.33
52-Week Range:
$1.35
$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.83 | 378.22M | 35.11M | -79.20M | -88.62M | -4.3367 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Initiated | Guggenheim | Buy |
| Dec-05-25 | Resumed | Stifel | Buy |
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
Cadrenal Therapeutics (CVKD) CEO sells 8,285 shares in planned trades - Stock Titan
Acumen (NASDAQ: ABOS) director equity grant tied to RA Capital funds - Stock Titan
Recursion (NASDAQ: RXRX) director sells 40,000 shares under 10b5-1 plan - Stock Titan
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
4 Biotech Stocks Investors Should Watch in 2026 - TradingView
Fierce Biotech Layoff Tracker 2026: Fulcrum cuts 85% of staff; Novartis trims research team - Fierce Biotech
Recursion (RXRX) director Bumpus sells 4,386 shares under Rule 10b5-1 plan - Stock Titan
Alnylam Pharmaceuticals (ALNY) Partners with Inceptive Nucleics to Enhance Drug Discovery - GuruFocus
ADHD medication shortage reported by pharmaceutical companies - FOX Carolina News
XFOR: Advancing an oral therapy for chronic neutropenia with pivotal data in 2027 and FDA approval targeted for 2028 - TradingView
Justice Jackson Pens Unanimous Decision Backed by SCOTUS Conservatives - Newsweek
FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY - TradingView
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy - Biogen
RIGEL (RIGL) CEO uses 2,424 shares for tax-withholding, retains large stake - Stock Titan
[Form 4] IONIS PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
Alnylam (ALNY) director sells 3,830 shares after expiring option exercise - Stock Titan
Baker funds tied to ACAD (ACAD) report RSU and stock option grants - Stock Titan
Crinetics (NASDAQ: CRNX) CEO reports 1.94M share gifts and trust transfers - Stock Titan
XFOR Initiated Coverage by Leerink Partners -- Rating Outperform - GuruFocus
Leerink initiates X4 Pharmaceuticals stock with outperform rating - Investing.com
Leerink Partners Initiates X4 Pharmaceuticals at Outperform With $12 Price Target - marketscreener.com
Layoff Tracker: Merck continues New Jersey cuts, laying off 88 in Rahway - BioSpace
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
FULL HOUSE RESORTS TO BREAK GROUND ON THE PERMANENT AMERICAN PLACE CASINO - Weekly Voice
Fennec Pharmaceuticals (FENC) CMO receives 168-share grant, holds 21,015 - Stock Titan
Trump Is Being Sued For Rescheduling Marijuana By Doctors And A Pharmaceutical Company Who Are 'Aggrieved' By The Move - Marijuana Moment
Viking Therapeutics, Inc. (VKTX) Stock Price, News, Quote & History - Yahoo Finance
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
X4 Pharmaceuticals (XFOR) Gains 2.73% as Stock Tests Key Resistance LevelsRating Change - The Legal Advocate
Is MYGN Stock a Buy at 0.4x Sales? What Investors Should Weigh - TradingView
Recursion (NASDAQ: RXRX) director sells 40,000 shares in planned trade - Stock Titan
X4 Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference - The Manila Times
XFOR Q1 2026 Earnings: EPS Beats Estimates Despite Continued Pre-Revenue Status; Stock DeclinesQuarterly Earnings Report - thelegaladvocate.com
Torrent Pharmaceuticals Ltd. Hits All-Time High of Rs 4,698.8 as Momentum Builds Across Timeframes - Markets Mojo
Phathom (PHAT) director James Topper receives 24,122 RSUs in equity grant - Stock Titan
Universe Pharmaceuticals (NASDAQ: UPC) CEO receives share grants under 2026 equity plan - Stock Titan
[Form 4] INOVIO PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
How The X4 Pharmaceuticals (XFOR) Story Is Shifting With Mavorixafor And New EU Progress - Yahoo Finance
Bears are Losing Control Over X4 Pharmaceuticals (XFOR), Here's Why It's a 'Buy' Now - sharewise.com
Can Encompass Health's Expansion Strategy Make It a Hold for Now? - TradingView
X4 Pharmaceuticals (XFOR) Q1 2026 Earnings: Why the Beat MattersDebt Analysis Report - The Legal Advocate
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
[EFFECT] X4 Pharmaceuticals, Inc SEC Filing - Stock Titan
Perceptive group holds 7.3% of X4 Pharmaceuticals (NASDAQ: XFOR) with exercisable warrants - Stock Titan
This Insider Has Just Sold Shares In X4 Pharmaceuticals - simplywall.st
ANIP Valuation: Does 9.8x Forward P/E Offer Upside? - TradingView
Apellis (NASDAQ: APLS) director tenders shares for $41 cash plus CVR - Stock Titan
Biogen deal: Apellis (APLS) VP tenders 65,955 shares, options cancelled - Stock Titan
Apellis (NASDAQ: APLS) director cashes out shares and options in Biogen tender offer - Stock Titan
Apellis (APLS) R&D chief converts stock and options to cash and CVRs in Biogen merger - Stock Titan
[Form 4] Apellis Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):